Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38)

Japan Diabetes Clinical Data Management Study Group (JDDM)

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims/Introduction: We carried out an observational cohort study to examine the relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetics. Materials and Methods: We analyzed the CoDiC ® database of the Japan Diabetes Data Management Study Group across 67 institutions in Japan. In a total of 3,698 drug-naïve patients who were initiated with metformin, dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulfonylurea (SU) from 2007 to 2012, we evaluated body mass index (BMI) and hemoglobin A1c (HbA1c). The patients were stratified according to their clinical features, and matched using a propensity score to adjust for baseline factors. Results: HbA1c was reduced with all drugs, with the largest effect elicited by DPP-4i and the smallest by SU (P = 0.00). HbA1c increased with SU after 6 months in the patients stratified by an age-of-onset of <50 years (P = 0.00). BMI increased with SU in the patients stratified by a BMI of <25 (P = 0.00), and decreased with metformin in the patients with a BMI >25 (P = 0.00). The reduction in HbA1c was larger in patients with HbA1c of ≥8%, compared with that in patients with HbA1c of <8% (P = 0.00). HbA1c during the study period was higher in patients who were added to or swapped with other drug(s), than in patients continued on the original drug (P = 0.00). Conclusions: The effect on bodyweight and glycemic control differed among metformin, DPP-4i and SU, and the difference was associated with clinical features.

Original languageEnglish
Pages (from-to)386-395
Number of pages10
JournalJournal of Diabetes Investigation
Volume7
Issue number3
DOIs
Publication statusPublished - 2016 May 1
Externally publishedYes

Fingerprint

Hypoglycemic Agents
Hemoglobins
Dipeptidyl-Peptidase IV Inhibitors
Metformin
Pharmaceutical Preparations
Japan
Propensity Score
Age of Onset
Observational Studies
Body Mass Index
Cohort Studies
Databases

Keywords

  • Oral antidiabetic drug
  • Propensity score-matched cohort study
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). / Japan Diabetes Clinical Data Management Study Group (JDDM).

In: Journal of Diabetes Investigation, Vol. 7, No. 3, 01.05.2016, p. 386-395.

Research output: Contribution to journalArticle

Japan Diabetes Clinical Data Management Study Group (JDDM). / Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). In: Journal of Diabetes Investigation. 2016 ; Vol. 7, No. 3. pp. 386-395.
@article{ea31d140189c422fae9e9c246fcb2f86,
title = "Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38)",
abstract = "Aims/Introduction: We carried out an observational cohort study to examine the relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetics. Materials and Methods: We analyzed the CoDiC {\circledR} database of the Japan Diabetes Data Management Study Group across 67 institutions in Japan. In a total of 3,698 drug-na{\"i}ve patients who were initiated with metformin, dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulfonylurea (SU) from 2007 to 2012, we evaluated body mass index (BMI) and hemoglobin A1c (HbA1c). The patients were stratified according to their clinical features, and matched using a propensity score to adjust for baseline factors. Results: HbA1c was reduced with all drugs, with the largest effect elicited by DPP-4i and the smallest by SU (P = 0.00). HbA1c increased with SU after 6 months in the patients stratified by an age-of-onset of <50 years (P = 0.00). BMI increased with SU in the patients stratified by a BMI of <25 (P = 0.00), and decreased with metformin in the patients with a BMI >25 (P = 0.00). The reduction in HbA1c was larger in patients with HbA1c of ≥8{\%}, compared with that in patients with HbA1c of <8{\%} (P = 0.00). HbA1c during the study period was higher in patients who were added to or swapped with other drug(s), than in patients continued on the original drug (P = 0.00). Conclusions: The effect on bodyweight and glycemic control differed among metformin, DPP-4i and SU, and the difference was associated with clinical features.",
keywords = "Oral antidiabetic drug, Propensity score-matched cohort study, Type 2 diabetes mellitus",
author = "{Japan Diabetes Clinical Data Management Study Group (JDDM)} and Azuma Kanatsuka and Yasunori Sato and Koichi Kawai and Koichi Hirao and Masashi Kobayashi and Atsunori Kashiwagi and Nobuyuki Abe and Keiko Arai and Hiroshi Fujiya and Yoshihide Fukumoto and Fumihiko Dake and Tomohiro Iizumi and Masaaki Ito and Koichi Iwasaki and Akira Kanamori and Sumio Kato and Masakazu Kato and Akira Kawara and Kenichi Kimura and Kazumasa Chikamori and Kotaro Iemitsu and Shigetake Kou and Mikihiko Kudo and Yoshio Kurihara and Gendai Lee and Akira Tsuruoka and Naoki Manda and Kiyokazu Matoba and Hiroshi Hayashi and Masae Minami and Nobuichi Kuribayashi and Kazuhiro Miyazawa and Yasuko Chiba and Takeshi Osonoi and Shin Nakamura and Hideo Sasaki and Katsutoshi Komori and Mariko Oishi and Akira Okada and Fuminobu Okuguchi and Morifumi Yanagisawa and Hidekatsu Sugimoto and Hiromichi Sugiyama and Masahiko Takai and Masato Takaki and Hiroshi Takamura and Hiroshi Takeda and Kokichi Tanaka and Takashi Miwa and Osamu Tomonaga",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/jdi.12430",
language = "English",
volume = "7",
pages = "386--395",
journal = "Journal of Diabetes Investigation",
issn = "2040-1116",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "3",

}

TY - JOUR

T1 - Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38)

AU - Japan Diabetes Clinical Data Management Study Group (JDDM)

AU - Kanatsuka, Azuma

AU - Sato, Yasunori

AU - Kawai, Koichi

AU - Hirao, Koichi

AU - Kobayashi, Masashi

AU - Kashiwagi, Atsunori

AU - Abe, Nobuyuki

AU - Arai, Keiko

AU - Fujiya, Hiroshi

AU - Fukumoto, Yoshihide

AU - Dake, Fumihiko

AU - Iizumi, Tomohiro

AU - Ito, Masaaki

AU - Iwasaki, Koichi

AU - Kanamori, Akira

AU - Kato, Sumio

AU - Kato, Masakazu

AU - Kawara, Akira

AU - Kimura, Kenichi

AU - Chikamori, Kazumasa

AU - Iemitsu, Kotaro

AU - Kou, Shigetake

AU - Kudo, Mikihiko

AU - Kurihara, Yoshio

AU - Lee, Gendai

AU - Tsuruoka, Akira

AU - Manda, Naoki

AU - Matoba, Kiyokazu

AU - Hayashi, Hiroshi

AU - Minami, Masae

AU - Kuribayashi, Nobuichi

AU - Miyazawa, Kazuhiro

AU - Chiba, Yasuko

AU - Osonoi, Takeshi

AU - Nakamura, Shin

AU - Sasaki, Hideo

AU - Komori, Katsutoshi

AU - Oishi, Mariko

AU - Okada, Akira

AU - Okuguchi, Fuminobu

AU - Yanagisawa, Morifumi

AU - Sugimoto, Hidekatsu

AU - Sugiyama, Hiromichi

AU - Takai, Masahiko

AU - Takaki, Masato

AU - Takamura, Hiroshi

AU - Takeda, Hiroshi

AU - Tanaka, Kokichi

AU - Miwa, Takashi

AU - Tomonaga, Osamu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Aims/Introduction: We carried out an observational cohort study to examine the relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetics. Materials and Methods: We analyzed the CoDiC ® database of the Japan Diabetes Data Management Study Group across 67 institutions in Japan. In a total of 3,698 drug-naïve patients who were initiated with metformin, dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulfonylurea (SU) from 2007 to 2012, we evaluated body mass index (BMI) and hemoglobin A1c (HbA1c). The patients were stratified according to their clinical features, and matched using a propensity score to adjust for baseline factors. Results: HbA1c was reduced with all drugs, with the largest effect elicited by DPP-4i and the smallest by SU (P = 0.00). HbA1c increased with SU after 6 months in the patients stratified by an age-of-onset of <50 years (P = 0.00). BMI increased with SU in the patients stratified by a BMI of <25 (P = 0.00), and decreased with metformin in the patients with a BMI >25 (P = 0.00). The reduction in HbA1c was larger in patients with HbA1c of ≥8%, compared with that in patients with HbA1c of <8% (P = 0.00). HbA1c during the study period was higher in patients who were added to or swapped with other drug(s), than in patients continued on the original drug (P = 0.00). Conclusions: The effect on bodyweight and glycemic control differed among metformin, DPP-4i and SU, and the difference was associated with clinical features.

AB - Aims/Introduction: We carried out an observational cohort study to examine the relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetics. Materials and Methods: We analyzed the CoDiC ® database of the Japan Diabetes Data Management Study Group across 67 institutions in Japan. In a total of 3,698 drug-naïve patients who were initiated with metformin, dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulfonylurea (SU) from 2007 to 2012, we evaluated body mass index (BMI) and hemoglobin A1c (HbA1c). The patients were stratified according to their clinical features, and matched using a propensity score to adjust for baseline factors. Results: HbA1c was reduced with all drugs, with the largest effect elicited by DPP-4i and the smallest by SU (P = 0.00). HbA1c increased with SU after 6 months in the patients stratified by an age-of-onset of <50 years (P = 0.00). BMI increased with SU in the patients stratified by a BMI of <25 (P = 0.00), and decreased with metformin in the patients with a BMI >25 (P = 0.00). The reduction in HbA1c was larger in patients with HbA1c of ≥8%, compared with that in patients with HbA1c of <8% (P = 0.00). HbA1c during the study period was higher in patients who were added to or swapped with other drug(s), than in patients continued on the original drug (P = 0.00). Conclusions: The effect on bodyweight and glycemic control differed among metformin, DPP-4i and SU, and the difference was associated with clinical features.

KW - Oral antidiabetic drug

KW - Propensity score-matched cohort study

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84948168962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948168962&partnerID=8YFLogxK

U2 - 10.1111/jdi.12430

DO - 10.1111/jdi.12430

M3 - Article

VL - 7

SP - 386

EP - 395

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

SN - 2040-1116

IS - 3

ER -